Baxter Drug Patent Portfolio
Baxter owns 12 orange book drugs protected by 37 US patents with Clinolipid 20% having the least patent protection, holding only 1 patent. And Nouress with maximum patent protection, holding 19 patents. Given below is the list of Baxter's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12447190 | 27 Sep, 2044 | Active | |
| US11173189 | Daptomycin formulations containing a combination of sorbitol and mannitol | 11 Mar, 2041 | Active |
| US12097170 | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation | 08 Mar, 2041 | Active |
| US12290494 | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation | 08 Mar, 2041 | Active |
| US10493051 | Cysteine composition and injection | 15 Mar, 2039 | Active |
| US10543186 | Cysteine composition and injection | 15 Mar, 2039 | Active |
| US10702490 | Cysteine composition and injection | 15 Mar, 2039 | Active |
| US11045438 | Cysteine composition and injection | 15 Mar, 2039 | Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use | 02 Mar, 2039 | Active |
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use | 15 Jan, 2039 | Active |
| US12403173 | 15 Dec, 2037 | Active | |
| US7635773 | Sulfoalkyl ether cyclodextrin compositions | 13 Mar, 2029 | Active |
| US6900184 | Compositions containing pipercillin and tazobactam useful for injection | 14 Apr, 2023 | Expired |
| US7915229 | Compositions containing piperacillin and tazobactam useful for injection | 14 Apr, 2023 | Expired |
| US8133883 | Compositions containing piperacillin and tazobactam useful for injection | 14 Apr, 2023 | Expired |
| US6869939 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin | 04 May, 2022 | Expired |
| US6310094 | Ready-to-use esmolol solution | 12 Jul, 2021 | Expired |
| US6528540 | Esmolol formulation | 12 Jul, 2021 | Expired |
| US6310094 | Ready-to-use esmolol solution | 12 Jan, 2021 | Expired |
| US6528540 | Esmolol formulation | 12 Jan, 2021 | Expired |
| US6207661 | Premixed formulation of piperacillin sodium and tazobactam sodium injection | 22 Feb, 2019 | Expired |
| US5840757 | Lipid emulsion intended for parenteral or enteral feeding | 24 Nov, 2015 | Expired |
| US5617906 | Container for anaesthetic agent | 08 Oct, 2014 | Expired |
| US5617906 | Container for anaesthetic agent | 08 Apr, 2014 | Expired |
Latest Legal Activities on Baxter's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Baxter.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 15 Apr, 2024 | US8133883 |
| Mail O.P. Petition Decision | 29 Dec, 2023 | US10702490 |
|
Email Notification
Critical
| 29 Dec, 2023 | US10702490 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 26 Dec, 2023 | US10702490 |
| Record Petition Decision of Granted to Make Entity Status large | 22 Dec, 2023 | US10702490 |
| O.P. Petition Decision | 22 Dec, 2023 | US10702490 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 01 Nov, 2023 | US10653719 |
|
Maintenance Fee Reminder Mailed
Critical
| 30 Oct, 2023 | US8133883 |
| Petition Entered | 16 Oct, 2023 | US10702490 |
| Payment of Maintenance Fee under 1.28(c) | 16 Oct, 2023 | US10702490 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 15 Oct, 2023 | US10702490 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Oct, 2023 | US10702490 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 11 Oct, 2023 | US10702490 |
| Post Issue Communication - Certificate of Correction | 27 Sep, 2023 | US11510942 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Aug, 2023 | US10583155 |
Baxter's Drug Patent Litigations
Baxter's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US5840757. The petitioner , challenged the validity of this patent, with DUTOT as the respondent. Click below to track the latest information on how companies are challenging Baxter's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11642370 | February, 2024 |
Institution Denied
(08 Aug, 2024)
| Exela Pharma Sciences, LLC | Nexus Pharmaceuticals LLC |
| US10653719 | September, 2020 |
Institution Denied
(23 Apr, 2021)
| Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 |
Institution Denied
(15 Dec, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10583155 | June, 2020 |
Terminated-Denied
(15 Dec, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 |
Institution Denied
(18 Nov, 2020)
| Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
| US6310094 | November, 2015 |
Institution Denied
(27 Apr, 2016)
| Baxter International Inc. et al. | Mylan Pharmaceuticals Inc. et al. |
| US6310094 | November, 2015 |
Terminated-Denied
(27 Apr, 2016)
| Baxter International Inc. | Mylan Pharmaceuticals Inc. |
| US6528540 | November, 2015 |
Institution Denied
(27 Apr, 2016)
| Baxter International Inc. et al. | Mylan Pharmaceuticals Inc. et al. |
| US6528540 | November, 2015 |
Terminated-Denied
(27 Apr, 2016)
| Baxter International Inc. | Mylan Pharmaceuticals Inc. |
| US5840757 | January, 1 |
Decision
(29 Jul, 1998)
| DUTOT | |
Baxter's Family Patents
Recent FDA approvals and tentative approvals for Baxter
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Innovator drugs
Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Epinephrine Bitartrate In 0.9% Sodium Chloride |
SUPPL-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Manufacturing (CMC) | 29 Sep, 2025 |
| Argatroban |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 5 - New Formulation or New Manufacturer | 28 Jul, 2010 |
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Propofol |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 23 Dec, 1998 |
Baxter Drug List
Given below is the complete list of Baxter's drugs and the patents protecting them.
1. Brevibloc
Brevibloc is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6310094
(Pediatric)
| Ready-to-use esmolol solution |
12 Jul, 2021
(4 years ago)
| Expired |
| US6528540
(Pediatric)
| Esmolol formulation |
12 Jul, 2021
(4 years ago)
| Expired |
| US6310094 | Ready-to-use esmolol solution |
12 Jan, 2021
(4 years ago)
| Expired |
| US6528540 | Esmolol formulation |
12 Jan, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brevibloc's drug page
2. Brevibloc Double Strength In Plastic Container
Brevibloc Double Strength In Plastic Container is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6310094
(Pediatric)
| Ready-to-use esmolol solution |
12 Jul, 2021
(4 years ago)
| Expired |
| US6528540
(Pediatric)
| Esmolol formulation |
12 Jul, 2021
(4 years ago)
| Expired |
| US6310094 | Ready-to-use esmolol solution |
12 Jan, 2021
(4 years ago)
| Expired |
| US6528540 | Esmolol formulation |
12 Jan, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brevibloc Double Strength In Plastic Container's drug page
3. Brevibloc In Plastic Container
Brevibloc In Plastic Container is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6310094
(Pediatric)
| Ready-to-use esmolol solution |
12 Jul, 2021
(4 years ago)
| Expired |
| US6528540
(Pediatric)
| Esmolol formulation |
12 Jul, 2021
(4 years ago)
| Expired |
| US6310094 | Ready-to-use esmolol solution |
12 Jan, 2021
(4 years ago)
| Expired |
| US6528540 | Esmolol formulation |
12 Jan, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brevibloc In Plastic Container's drug page
4. Clinolipid 20%
Clinolipid 20% is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5840757 | Lipid emulsion intended for parenteral or enteral feeding |
24 Nov, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clinolipid 20%'s drug page
5. Dapzura Rt
Dapzura Rt is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11173189 | Daptomycin formulations containing a combination of sorbitol and mannitol |
11 Mar, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dapzura Rt's drug page
Explore Our Curated Drug Screens
6. Micafungin In Sodium Chloride 0.9%
Micafungin In Sodium Chloride 0.9% is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12403173 |
15 Dec, 2037
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Micafungin In Sodium Chloride 0.9%'s drug page
7. Nexterone
Nexterone is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7635773 | Sulfoalkyl ether cyclodextrin compositions |
13 Mar, 2029
(3 years from now)
| Active |
| US6869939 | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
04 May, 2022
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nexterone's drug page
8. Norepinephrine Bitartrate In 5% Dextrose
Norepinephrine Bitartrate In 5% Dextrose is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12097170 | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation |
08 Mar, 2041
(15 years from now)
| Active |
| US12290494 | Packaged, sealed container system for stable storage of an oxygen sensitive pharmaceutical formulation |
08 Mar, 2041
(15 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norepinephrine Bitartrate In 5% Dextrose's drug page
9. Nouress
Nouress is protected by 19 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10493051 | Cysteine composition and injection |
15 Mar, 2039
(13 years from now)
| Active |
| US10543186 | Cysteine composition and injection |
15 Mar, 2039
(13 years from now)
| Active |
| US10702490 | Cysteine composition and injection |
15 Mar, 2039
(13 years from now)
| Active |
| US11045438 | Cysteine composition and injection |
15 Mar, 2039
(13 years from now)
| Active |
| US11510941 | Stable, highly pure L-cysteine compositions for injection and methods of use |
02 Mar, 2039
(13 years from now)
| Active |
| US10478453 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10583155 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10653719 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10905713 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10905714 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10912795 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10918662 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US10933089 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11510942 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11642370 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11648262 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11679125 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11684636 | Stable, highly pure l-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
| US11826383 | Stable, highly pure L-cysteine compositions for injection and methods of use |
15 Jan, 2039
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nouress's drug page
10. Suprane
Suprane is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5617906
(Pediatric)
| Container for anaesthetic agent |
08 Oct, 2014
(11 years ago)
| Expired |
| US5617906 | Container for anaesthetic agent |
08 Apr, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Suprane's drug page
11. Vasopressin In Sodium Chloride 0.9%
Vasopressin In Sodium Chloride 0.9% is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12447190 |
27 Sep, 2044
(18 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vasopressin In Sodium Chloride 0.9%'s drug page
12. Zosyn In Plastic Container
Zosyn In Plastic Container is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6900184 | Compositions containing pipercillin and tazobactam useful for injection |
14 Apr, 2023
(2 years ago)
| Expired |
| US7915229 | Compositions containing piperacillin and tazobactam useful for injection |
14 Apr, 2023
(2 years ago)
| Expired |
| US8133883 | Compositions containing piperacillin and tazobactam useful for injection |
14 Apr, 2023
(2 years ago)
| Expired |
| US6207661 | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
22 Feb, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zosyn In Plastic Container's drug page